ArticleJournal of the Egyptian National Cancer Institute2026
Prospective evaluation of dose rate effects on acute radiation toxicities and quality of life in head and neck cancer.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the influence of different dose rates on the radiation-related adverse events. MATERIALS AND
methodsThe study involved 60 patients divided into three groups, each receiving different dose rates of the Flattening Filter-Free (FFF) 6MV IMRT technique: 20 patients at 600, 20 at 1000, and 20 at 1400. Acute adverse events were monitored weekly. The EORTC-translated QLQ-H&N 35 questionnaire was used to assess health-related quality of life (QoL) according to established EORTC criteria during radiotherapy.
resultsDuring the initial phase of radiotherapy treatment, no significant differences were noted in the prevalence of conditions such as mucositis and weight loss among the treatment groups. However, weight loss showed a significant variation (p = 0.028) at third week for the 600-dose rate group. From the fourth to fifth week, no notable differences emerged for mucositis and xerostomia among groups, while increase radiation dose rate was correlated with significant rise in dermatitis and dysphagia (p = 0.020 and p = 0.036, respectively). Similarly, from week five to six and from week six to seven, no significant differences were observed for mucositis. Yet significant increase in xerostomia and other conditions was evident with rising radiation dose rate. The evaluation of the QLQ-H&N 35 for head and neck cancer patients revealed a numerical scale for symptom severity, from 1 (not at all) to 4 (very much). While differences in symptom intensity across dose rates were noted, they did not reach statistical significance.
conclusionThe dose rate appears to influence patient health outcomes, although it does not seem to affect the QoL during the period of radiotherapy course treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.